Aarti Drugs
Aarti Drugs Limited, commonly referred to as Aarti Drugs, is a prominent player in the pharmaceutical industry, headquartered in Mumbai, India. Established in 1984, the company has made significant strides in the production of active pharmaceutical ingredients (APIs) and formulations, catering to both domestic and international markets. With a diverse portfolio that includes anti-infectives, analgesics, and cardiovascular medications, Aarti Drugs stands out for its commitment to quality and innovation. The company has achieved several milestones, including regulatory approvals from major global health authorities, which solidify its market position. Recognised for its robust manufacturing capabilities and a strong emphasis on research and development, Aarti Drugs continues to contribute to the healthcare sector, ensuring the availability of essential medicines worldwide.
DitchCarbon Score
How does Aarti Drugs's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Aarti Drugs's score of 24 is higher than 91% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Aarti Drugs's reported carbon emissions
In 2023, Aarti Drugs reported total carbon emissions of approximately 133,040,000 kg CO2e, comprising about 56,820,000 kg CO2e from Scope 1 and about 76,414,000 kg CO2e from Scope 2. This represents a significant reduction from 2022, where emissions were approximately 136,703,000 kg CO2e, indicating a proactive approach to lowering their carbon footprint. The company has demonstrated a consistent commitment to reducing emissions over the years. In 2021, Aarti Drugs emitted about 128,800,000 kg CO2e, which decreased to approximately 133,040,000 kg CO2e in 2023. This trend reflects their ongoing efforts to enhance operational efficiency and reduce greenhouse gas emissions. Despite the absence of specific reduction targets or climate pledges, Aarti Drugs continues to focus on improving their emissions intensity, achieving approximately 5.333 kg CO2e per rupee of turnover in 2023. The company is actively working towards sustainability, aligning with industry standards for climate action.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 84,380,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 104,966,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Aarti Drugs is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
